Amparo Navea

Dr. Amparo Navea

Universidad Cardenal Herrera-CEU, CEU Universities
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
JAJose M. Artigas
Jose M. Artigas
AFAdelina Felipe
Adelina Felipe
Amparo NaveaAmparo Navea
Amparo Navea
AFAdriana Fandiño
Adriana Fandiño
CACristina Artigas
Cristina Artigas
Purpose.: To experimentally measure the spectral transmission of human crystalline lenses belonging to adult and elderly persons, and to determine the color and total transmission of visible light of such crystalline lenses. Methods.: The spectral transmission curve of 32 human crystalline lenses was measured using a PerkinElmer 800UV/VIS spectrometer. Total transmission of visible light and the chromatic coordinates of these crystalline lenses were determined from these curves for solar illumination. Results.: The crystalline lens that filters UV and its transmission in the visible spectrum decreases with age; such a decrease is greater for short wavelengths. The total transmission of visible light decreases, especially after the age of 70 years, and the crystalline color becomes yellower and saturated. Conclusions.: The great variability existing in the spectral transmission of the human crystalline lens is lesser between the ages of 40 and 59 years, but greater from the age of 60 and older. The decrement in transmittance between these two age groups varies from 40% for 420 nm to 18% for 580 nm. Nevertheless, it is proven that age is not the only parameter affecting crystalline transmission. In the range of 40 to 59 years, age does not bear an influence on total transmission of light, but from 60 years and older it does. Moreover, the light transmitted decreases with age. This total transmission of light is similar to or lower than the amount that the different intraocular lenses transmit, even with a yellow or orange filter. The color of the human lens becomes yellowish and saturated with age. RESUMEN

1 April 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
FBFrancisco Bosch-Morell
Francisco Bosch-Morell
MSMérida Salvador
Mérida Salvador
Amparo NaveaAmparo Navea
Amparo Navea
Myopia affected approximately 1.6 billion people worldwide in 2000, and it is expected to increase to 2.5 billion by 2020. Although optical problems can be corrected by optics or surgical procedures, normal myopia and high myopia are still an unsolved medical problem. They frequently predispose people who have them to suffer from other eye pathologies: retinal detachment, glaucoma, macular hemorrhage, cataracts, and so on being one of the main causes of visual deterioration and blindness. Genetic and environmental factors have been associated with myopia. Nevertheless, lack of knowledge in the underlying physiopathological molecular mechanisms has not permitted an adequate diagnosis, prevention, or treatment to be found. Nowadays several pieces of evidence indicate that oxidative stress may help explain the altered regulatory pathways in myopia and the appearance of associated eye diseases. On the one hand, oxidative damage associated with hypoxia myopic can alter the neuromodulation that nitric oxide and dopamine have in eye growth. On the other hand, radical superoxide or peroxynitrite production damage retina, vitreous, lens, and so on contributing to the appearance of retinopathies, retinal detachment, cataracts and so on. The objective of this review is to suggest that oxidative stress is one of the key pieces that can help solve this complex eye problem.

1 January 2009 in Ophthalmology
Verified
Journal Article
Closed access
ABAnna Boixadera
Anna Boixadera
JGJosé García-Arumí
José García-Arumí
JAJosé García Arumí
José García Arumí
VMVicente Martínez-Castillo
Vicente Martínez-Castillo
JEJose Luis Encinas
Jose Luis Encinas
JOJose Luis Olea
Jose Luis Olea

3 November 2006 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
EAE Aller
E Aller
TJT Jaijo
T Jaijo
MBM Beneyto
M Beneyto
CNC Nájera
C Nájera
SOSilvestre Oltra
Silvestre Oltra
JMJose Millan
Jose Millan
Mutations in USH2A gene have been shown to be responsible for Usher syndrome type II, an autosomal recessive disorder characterised by hearing loss and retinitis pigmentosa. USH2A was firstly described as consisting of 21 exons, but 52 novel exons at the 3’ end of the gene were recently identified. In this report, a mutation analysis of the new 52 exons of USH2A gene was carried out in 32 unrelated patients in which both disease-causing mutations could not be found after the screening of the first 21 exons of the USH2A gene. On analysing the new 52 exons, fourteen novel mutations were identified in 14 out of the 32 cases studied, including 7 missense, 5 frameshift, 1 duplication and a putative splice-site mutation.

1 August 2016 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CBCecilia Barbas-Bernardos
Cecilia Barbas-Bernardos
EAEmily G. Armitage
Emily G. Armitage
AGAntonia García
Antonia García
SMSalvador Mérida
Salvador Mérida
Amparo NaveaAmparo Navea
Amparo Navea
CBCoral Barbas
Coral Barbas

1 February 1994 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
MDM Diaz-Llopis
M Diaz-Llopis
EEE Espana
E Espana
GMG Munoz
G Munoz
Amparo NaveaAmparo Navea
Amparo Navea
ECE Chipont
E Chipont
FRFrancisco J. Romero
Francisco J. Romero
The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied. Foscarnet in a dose of 2400 micrograms was injected directly into the vitreous of 11 patients (15 eyes). Five patients had active retinitis (eight eyes, 53.3%), and received a 3 week induction therapy of six injections as the first step. Six patients had initial inactive retinitis (seven eyes, 46.7%), and received only maintenance therapy which consisted of a weekly injection. The main indications for intravitreal therapy were: myelosuppression, kidney toxicity, catheter related sepsis, or refusal of intravenous therapy. The patients were followed for a mean period of 16 weeks (range 8-28 weeks) and received a total of 304 injections. Vitreous foscarnet levels were measured by high performance liquid chromatography. After a 3 week course of induction therapy, complete resolution of the active retinitis was seen in 62.5% (5/8 cases), while 37.5% (3/8 cases) had partial resolution. No cases failed to respond or progress. The rate of relapse on maintenance therapy was 33% (five of 15 eyes) by 20 weeks, and two of these eyes did not respond to reinduction and progressed in involvement of the macula or optic nerve. Neither important local complications nor intraocular drug toxicity were observed. Vitreous foscarnet levels in two different patients were 896 mumol/l and 74.9 mumol/l at 22 3/4 hours and 42 1/2 hours after the injection. Intravitreal foscarnet appears to be a safe, effective, and useful alternative in patients with intolerance to intravenous and viral therapy.